Previous 10 | Next 10 |
home / stock / eypt / eypt articles
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commerci...
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Camtek Ltd. (NASDAQ: CAMT) is a "fabulous" company, but the stoc...
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Daktronics posted quarterly ...
U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) moved higher duri...
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in the...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Monday. The Dow traded down 0.17% to 36,...
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Monday. The Dow traded down 0.36% to 36,116.18...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...